Kazuhiro Abeyama1, Ikuro Maruyama
1Department of Preventive Medicine (SNBL Funded), Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences.
Sepsis and systemic inflammatory response syndrome (SIRS) involve high mobility group box-1 (HMGB1) protein, a key mediator of inflammation and lethality. A novel therapeutic strategy involves functional HMGB1 inhibition using thrombomodulin for sepsis/SIRS/DIC.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: